200% Dividend: Mid Cap Pharma Stock Declares 27% Surge In Revenue, Net Remains Flat

Mid cap pharmaceuticals sector stock, Ipca Laboratories Ltd on November 10, 2023 announced nearly flat rise of 0.81% in its consolidated net profit at Rs 145.06 crore for the quarter ended September 30, 2023 as against Rs 143.90 crore reported in the corresponding quarter of last year. Revenue from operations reported at Rs 2033.96 crore, up 27% as compared to Rs 1600.95 crore declared in the same quarter of last year. The company also declared an interim dividend of The company announced its earnings before interest, taxes, depreciation and amortization (EBITDA) at Rs 321.3 crore up from 260.6 crore in the year ago period. EBITDA margin announced at 15.8%, down from 16.3% in the year ago period. Check details below:

Ipca Laboratories Declares Interim Dividend: According to the BSE filing issued on November 10, 2023, "We also wish to inform you that, the Board has declared an interim dividend of Rs: 21- per equity share (200%) for the financial year 2023-24. Kindly note that vide our letter dated October 26, 2023, we have already informed you that 22nd November, 2023 has been fixed as the Record Date for ascertaining the members entitlement of said interim dividend now declared which will be paid by the Company to the eligible shareholders on or before 5th December, 2023."

Ipca Laboratories Stock Performance & Return: Last trading price of Ipca Laboratories share on BSE is Rs 1050.80 per share with intraday gain of 0.38% as on November 10, 2023. Its 52-week high price is Rs 1065.20 per share and 52-week low price is Rs 670.00 per share, respectively. The company has a market capitalisation of Rs 26,654.30 crore. Ipca Laboratories shares gained 17% in last 3-months, soared 51% in last 6-months, surged 26% YTD, and gained over 18% in last 1-year. In last 2-years, Ipca Laboratories shares declined 5% and rose 198% in last 5-years.

Disclaimer:

The stock just highlights the dividend and is not a recommendation to buy, sell or hold. We have not done fundamental or technical analysis and have no opinion on the stock mentioned. Neither, the author nor Greynium Information Technologies should be held liable for any losses. Please consult a professional advisor.